Alpha 2.0
Login Register
» Authors » Elisa Di Filippo

Elisa Di Filippo

Explore the profile of Elisa Di Filippo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 191
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Public Health
Top 10 Co-Authors
Franco Maggiolo
Marco Rizzi
Massimo Di Pietro
Laura Sighinolfi
Nicoletta Ladisa
Francesco Castelli
Elena Raffetti
Eugenia Quiros-Roldan
Daniela Valenti
Andrea Gori
Published In
J Acquir Immune Defic Syndr
AIDS
J Int AIDS Soc
PLoS One
BMC Public Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Vascular graft infections caused by BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature
Arsuffi S, Cambianica A, Di Filippo E, Ripamonti D, Tebaldi A, Arosio M, et al.
J Clin Tuberc Other Mycobact Dis . 2023 Mar; 31:100360. PMID: 36941969
Bacillus Calmette-Guerin (BCG) immunotherapy (i.e., intravesical instillation of live attenuated strain of ) is a standard of care for non-muscle-invasive bladder cancer (NMIBC). The risk of infective adverse events is...
2.
Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort
Maggiolo F, Valenti D, Teocchi R, Comi L, Di Filippo E, Rizzi M
J Int Assoc Provid AIDS Care . 2022 Jun; 21:23259582221101815. PMID: 35695220
adherence and forgiveness are key factors for virologic success. We evaluated them for 3TC/DTG. pharmacy refills were used to calculate the proportion of days covered (PDC). Forgiveness was calculated as...
3.
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, et al.
Antivir Ther . 2022 Apr; 26(3-5):51-57. PMID: 35485333
Background: Primary analysis at 24 weeks showed that switching to rilpivirine plus darunavir/cobicistat was non-inferior to continuing a standard three-drug antiretroviral regimen in virologically suppressed people with HIV. We present...
4.
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L, et al.
PLoS One . 2019 Oct; 14(10):e0223181. PMID: 31603906
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to evaluate the impact...
5.
Post-treatment controllers after treatment interruption in chronically HIV-infected patients
Maggiolo F, Di Filippo E, Comi L, Callegaro A
AIDS . 2018 Jan; 32(5):623-628. PMID: 29334553
Objective: Control HIV replication requires continuous combined antiretroviral therapy (cART) as discontinuation of cART results in a rapid viral rebound. However, a few individuals exist who took cART for several...
6.
Reduced adherence to antiretroviral therapy is associated with residual low-level viremia
Maggiolo F, Di Filippo E, Comi L, Callegaro A, Colombo G, Di Matteo S, et al.
Pragmat Obs Res . 2017 Jun; 8:91-97. PMID: 28603436
The source and significance of residual low-level viremia (LLV) during combinational antiretroviral therapy (cART) remain a matter of controversy. It is unclear whether residual viremia depends on ongoing release of...
7.
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort
Postorino M, Prosperi M, Foca E, Quiros-Roldan E, Di Filippo E, Maggiolo F, et al.
BMC Infect Dis . 2017 Mar; 17(1):212. PMID: 28298195
Background: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy...
8.
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort
Raffetti E, Postorino M, Castelli F, Casari S, Castelnuovo F, Maggiolo F, et al.
BMC Public Health . 2016 Aug; 16(1):878. PMID: 27557878
Background: We aimed at evaluating frequency and factors associated with late presentation and advanced HIV disease and excess risk of death due to these conditions from 1985 to 2013 among...
9.
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study
Quiros-Roldan E, Raffetti E, Castelli F, Foca E, Castelnuovo F, Di Pietro M, et al.
J Antimicrob Chemother . 2016 Aug; 71(12):3519-3527. PMID: 27543658
Objectives: We investigated the association between persistent low-level viraemia, measured as viraemia copy-years (VCY), and all-cause mortality. Methods: We included 3271 HIV-infected patients who initiated their first combined ART (cART)...
10.
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
Foca E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, et al.
Medicine (Baltimore) . 2016 Jul; 95(29):e4091. PMID: 27442636
Introduction: Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) suffer from faster progression of liver fibrosis (LF) and have greater risk of worse clinical outcomes. We...